TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19278785

Group type: EXPERIMENTAL
Intervention: Social observation (Group 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Conditioning procedure (Group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Verbal suggestion (Group 3)
Number of subjects: 3
Study: 18046223

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg and intravitreal triamcinolone (IVT) 2 mg
Number of subjects: 97

Group type: COMPARATOR
Intervention: Macular photocoagulation (MPC)
Number of subjects: 97
Study: 15522365

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 336

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Surgery (for patients with baseline VA > 20/200)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Observation (for patients with baseline VA > 20/200)
Number of subjects: 336
Study: 11403365

Group type: EXPERIMENTAL
Intervention: Presence of male gender
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Age > or = 65 years
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: High serum cholesterol (> 6.8 mmol/l)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: High serum creatinine (> 155 micromol/l)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Ischaemic heart disease
Number of subjects: 18790
Study: 9814867

Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine
Number of subjects: 1488

Group type: COMPARATOR
Intervention: Control treatments
Number of subjects: 1488
Study: 7877124

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 37
Study: 3358819

Group type: EXPERIMENTAL
Intervention: Alcohol intervention (mean serum ethanol concentration 93 mg/100 ml, S.D. 17)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no alcohol)
Number of subjects: 30
Study: 31539362

Group type: EXPERIMENTAL
Intervention: Home-based strength training (HBST)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 32
Study: 28431952

Group type: EXPERIMENTAL
Intervention: Preoperative patient education video
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patient perception of time spent with health care team
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Actual time spent with health care team
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: History of previous surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Severity of apical prolapse
Number of subjects: 100
Study: 25931141

Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 756
Study: 24043733

Group type: EXPERIMENTAL
Intervention: Daily manual lymphatic drainage and bandaging followed by compression garments
Number of subjects: 95

Group type: COMPARATOR
Intervention: Compression garments
Number of subjects: 95
Study: 21762907

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: I-Scan
Number of subjects: 142

Group type: COMPARATOR
Intervention: High-definition white-light colonoscopy
Number of subjects: 142
Study: 19500091

Group type: EXPERIMENTAL
Intervention: Enhanced Clinical Intervention (ECI) + Specialized Care for Bipolar Disorder (SCBD)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Specialized Care for Bipolar Disorder (SCBD)
Number of subjects: 463
Study: 16458700

Group type: EXPERIMENTAL
Intervention: 100 mg nimesulide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15268833

Group type: EXPERIMENTAL
Intervention: Pulsatile ocular blood flow (POBF) measurement in POAG patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pulsatile ocular blood flow (POBF) measurement in normal control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of POBF for diagnosis of POAG
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation between changes of visual field and POBF
Number of subjects: 100
Study: 11405809

Group type: EXPERIMENTAL
Intervention: Almotriptan malate, 12.5 mg
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Sumatriptan succinate, 50 mg
Number of subjects: 1173
Study: 9565006

Group type: EXPERIMENTAL
Intervention: ORG 10172 (danaparoid sodium)
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1281
Study: 7997377

Group type: EXPERIMENTAL
Intervention: 123I‐IBZM SPECT
Number of subjects: 58
Study: 3057120

Group type: EXPERIMENTAL
Intervention: Isoflurane (with and without nitrous oxide) at 0.5 MAC
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Isoflurane (with and without nitrous oxide) at 1.0 MAC
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Isoflurane (with and without nitrous oxide) at 1.5 MAC
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Halothane at 0.5 MAC
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Halothane at 1.0 MAC
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Halothane at 1.5 MAC
Number of subjects: 104
Study: 31965678

Group type: EXPERIMENTAL
Intervention: Intralesional methotrexate (MTX) 2 mg/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralesional saline (placebo)
Number of subjects: 60
Study: 30311037

Group type: EXPERIMENTAL
Intervention: Closed suction drain
Number of subjects: 161

Group type: COMPARATOR
Intervention: No closed suction drain
Number of subjects: 161
Study: 26982627

Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 52
Study: 25313848

Group type: EXPERIMENTAL
Intervention: Unfortified mother's own milk (MOM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: S‐26 fortified mother's own milk (MOM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: FM 85 fortified mother's own milk (MOM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2-hourly feeds
Number of subjects: 25

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 25
Study: 23389497

Group type: EXPERIMENTAL
Intervention: 3 additional doses of L-asparaginase (6000 IU/m2/dose) during consolidation treatment (3A arm)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard treatment without additional doses of L-asparaginase (0A arm)
Number of subjects: 117
Study: 22187762

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 60
Study: 19892856

Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo (detuned ultrasound therapy and detuned short‐wave therapy)
Number of subjects: 154
Study: 16564394

Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 29

Group type: COMPARATOR
Intervention: No earplugs
Number of subjects: 29
Study: 15328092

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate 2,000/125 mg
Number of subjects: 633

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 875/125 mg
Number of subjects: 633
Study: 12925082

Group type: EXPERIMENTAL
Intervention: Transverse coloplasty pouch (TCP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Colonic J-pouch (CJP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transverse coloplasty pouch (TCP) and Colonic J-pouch (CJP)
Number of subjects: 30
Study: 10780133

Group type: EXPERIMENTAL
Intervention: Mother present
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Blanket present
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mother plus blanket present
Number of subjects: 64

Group type: COMPARATOR
Intervention: No supportive agent
Number of subjects: 64
Study: 8622502

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen or chemoendocrine therapy
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Cytotoxic treatment
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Later cytotoxic therapy
Number of subjects: 2687

Group type: EXPERIMENTAL
Intervention: Anticipation of future therapy
Number of subjects: 2687

Group type: COMPARATOR
Intervention: Oestrogen-receptor-negative tumours
Number of subjects: 2687

Group type: COMPARATOR
Intervention: Number of involved axillary nodes
Number of subjects: 2687
Study: 1442685

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no cisapride)
Number of subjects: 14
Study: 4076841

Group type: EXPERIMENTAL
Intervention: Stanozolol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3119288

Group type: EXPERIMENTAL
Intervention: Levonorgestrel and Ethinylestradiol in tablet form (150/30)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Levonorgestrel and Ethinylestradiol in capsule form
Number of subjects: 9
Study: 31699127

Group type: EXPERIMENTAL
Intervention: Wilson's disease patients (n=61)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy control patients (n=61)
Number of subjects: 61
Study: 27169431

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25589424

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 154

Group type: COMPARATOR
Intervention: TVT-Secur
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study: 23043722

Group type: EXPERIMENTAL
Intervention: Enhanced feeding protocol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard feeding protocol
Number of subjects: 50
Study: 21798122

Group type: EXPERIMENTAL
Intervention: Print-based intervention (mailed printed materials)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 276
Study: 19199221

Group type: EXPERIMENTAL
Intervention: Motion Control Shoe (MC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cushioning Shoe (CU)
Number of subjects: 14
Study: 16891382

Group type: COMPARATOR
Intervention: 3-month weight-loss (vs. weight-stability) in AMI patients (OPTIMAAL trial)
Number of subjects: 4360

Group type: COMPARATOR
Intervention: 3-month weight-loss in AMI patients (CONSENSUS II trial)
Number of subjects: 4360

Group type: COMPARATOR
Intervention: 1-year weight-loss in stable CAD patients (4S trial)
Number of subjects: 4360

Group type: COMPARATOR
Intervention: Weight-gain in AMI patients (OPTIMAAL trial)
Number of subjects: 4360

Group type: COMPARATOR
Intervention: Weight-gain in AMI patients (CONSENSUS II trial)
Number of subjects: 4360

Group type: COMPARATOR
Intervention: Weight-gain in stable CAD patients (4S trial)
Number of subjects: 4360
Study: 14982548

Group type: EXPERIMENTAL
Intervention: Standard treatment plus CM with an expected maximum of $240 of reinforcement
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard treatment plus CM with an expected maximum of $80 of reinforcement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study: 11709606

Group type: EXPERIMENTAL
Intervention: Combination therapy including sulphasalazine (SSZ; 2000 mg/day), methotrexate (MTX; 7.5 mg/week), and prednisolone (initially 60 mg/day, tapered to 7.5 mg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: SSZ alone
Number of subjects: 155
Study: 9385898

Group type: EXPERIMENTAL
Intervention: Laser-facilitated PTCA
Number of subjects: 215

Group type: COMPARATOR
Intervention: Stand-alone PTCA
Number of subjects: 215
Study: 8196493

Group type: EXPERIMENTAL
Intervention: hCRH (100 ug i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: oCRH (100 ug i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3367455

Group type: EXPERIMENTAL
Intervention: Oral acyclovir, 400 mg five times daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30380017

Group type: EXPERIMENTAL
Intervention: Preconception lifestyle intervention targeting physical activity, diet, and behavior modification
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150
Study: 28350210

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 87
Study: 26163901

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Crossover group
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Quality of life improvement
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 294
Study: 24830913

Group type: EXPERIMENTAL
Intervention: Goal setting intervention by staff nurses during routine primary care visits
Number of subjects: 184

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 184
Study: 22005905

Group type: EXPERIMENTAL
Intervention: 10 mg of 0.5% hyperbaric bupivacaine (Group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5 mg of 0.5% hyperbaric bupivacaine combined with 2.5 μg sufentanil (Group II)
Number of subjects: 50
Study: 19272667

Group type: EXPERIMENTAL
Intervention: Integrated home care and discharge practice (IHCaD‐practice)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Usual care (non-trial group)
Number of subjects: 668
Study: 16822845

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 12624696

Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron orally
Number of subjects: 150

Group type: COMPARATOR
Intervention: 50 mg dolasetron orally plus 8 mg dexamethasone intravenously
Number of subjects: 150
Study: 11400961

Group type: COMPARATOR
Intervention: Single sentinel node removed
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Multiple sentinel nodes removed
Number of subjects: 1436
Study: 9230639

Group type: EXPERIMENTAL
Intervention: Idazoxan (selective alpha2 antagonist)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Idazoxan
Number of subjects: 33
Study: 8252951

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (10 mg/body square meters)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 21
Study: 3550340

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (bleomycin, Cytoxan, methotrexate, and 5-fluorouracil) in two cycles (one cycle if no tumor response) followed by standard treatment (combined irradiation and surgery or primary irradiation alone)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin and 5-fluorouracil) in three cycles prior to standard treatment
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (standard treatment without prior chemotherapy)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Experimental group (induction chemotherapy)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 143
Study: 30932012

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1500 kcal/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metformin and Hypocaloric diet
Number of subjects: 15
Study: 28791820

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of botulinum toxin type A (group II)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Occlusal splint therapy (group I)
Number of subjects: 10
Study: 25504483

Group type: EXPERIMENTAL
Intervention: Experimental group (5 training sessions using a prosthesis simulator)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (only performed the tests)
Number of subjects: 48
Study: 23913656

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 45 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 21143421

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vardenafil (20 mg)
Number of subjects: 49
Study: 19298296

Group type: EXPERIMENTAL
Intervention: 3.8 mm diameter abutment (test group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 5.5 mm diameter abutment (control group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bone filling in test group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bone filling in control group
Number of subjects: 22
Study: 17084785

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Naltrexone with fluoxetine
Number of subjects: 280

Group type: COMPARATOR
Intervention: Naltrexone placebo
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 280
Study: 15525560

Group type: EXPERIMENTAL
Intervention: Clofazimine with high fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine with orange juice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine with antacid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clofazimine with water (control)
Number of subjects: 0
Study: 11765155

Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional daylight phototherapy
Number of subjects: 109
Study: 9297047

Group type: EXPERIMENTAL
Intervention: Intracervical dinoprostone
Number of subjects: 389

Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 389
Study: 8277478

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 77

Group type: COMPARATOR
Intervention: Clindamycin and gentamicin
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Treatment failures
Number of subjects: 77
Study: 3688387

Group type: EXPERIMENTAL
Intervention: Nalbuphine and methohexitone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Fentanyl and diazepam
Number of subjects: 55
Study: 29969431

Group type: EXPERIMENTAL
Intervention: Pre-hospital ticagrelor
Number of subjects: 304
Study: 27752709

Group type: EXPERIMENTAL
Intervention: Functional regulator type II
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 23
Study: 24261460

Group type: EXPERIMENTAL
Intervention: Modifiable extrinsic risk factors
Number of subjects: 132

Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 132
Study: 21806682

Group type: EXPERIMENTAL
Intervention: Cross-linked collagen membrane (VN)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Native collagen membrane (BG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (absent RDH, 0 mm)
Number of subjects: 36
Study: 20723779

Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver (CRP)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CRP plus home exercise
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Modified CRP
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CRP for patients with involvement of two semicircular canals
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Self-CRP home exercise
Number of subjects: 118

Group type: COMPARATOR
Intervention: Self-CRP
Number of subjects: 118
Study: 18854540

Group type: EXPERIMENTAL
Intervention: Episodic amiodarone treatment
Number of subjects: 209

Group type: COMPARATOR
Intervention: Continuous amiodarone treatment
Number of subjects: 209
Study: 16227760

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg for 8 weeks
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 300/25 mg for 8 weeks
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ treatment regimen
Number of subjects: 1005
Study: 11863257

Group type: EXPERIMENTAL
Intervention: Omapatrilat (target dose 40 mg once daily)
Number of subjects: 12600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12600

Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 12600
Study: 10030553

Group type: EXPERIMENTAL
Intervention: Photocoagulation
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 3711

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 3711
Study: 7747690

Group type: EXPERIMENTAL
Intervention: High dose levosimendan (25 micrograms/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High dose levosimendan (25 micrograms/kg) during exercise at lower workload
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low dose levosimendan (6.5 micrograms/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High dose levosimendan (25 micrograms/kg) at higher workload
Number of subjects: 14
Study: 1294521

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Co-trimoxazole (1.92 g)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Ofloxacin (200 mg)
Number of subjects: 349
Study: 6733833

Group type: EXPERIMENTAL
Intervention: 4 mile continuous running at 75% of maximal heart rate (approximately 500 Cal/session)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 2 mile continuous running at 75% of maximal heart rate (approximately 250 Cal/session)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Interval running (1 min at 90% maximal heart rate followed by 3 min walking for eight sets, approximately 500 Cal/session)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 59
Study: 30761717

Group type: EXPERIMENTAL
Intervention: Cilostazol (CTZ) 200 mg/d
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin (ASA) 100 mg/d
Number of subjects: 100
Study: 29412363

Group type: EXPERIMENTAL
Intervention: Etodolac (400 mg) administered 1 hour prior to bleaching
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo administered 1 hour prior to bleaching
Number of subjects: 50
Study: 25091062

Group type: EXPERIMENTAL
Intervention: Antimicrobial susceptibility-guided therapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Clarithromycin-based triple therapy
Number of subjects: 114